This study is for people with HIV-1 who haven't taken HIV medicine before. The goal is to see if a new treatment, doravirine/islatravir (DOR/ISL), works as well as another treatment called bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). This study is "double-blind," meaning neither the doctors nor the participants know which treatment they're getting to make sure the results are fair. HIV-1 is a type of virus that attacks the immune system. To be part of this study, you must have at least 500 copies of the virus in your blood, and you must not have taken HIV medicine before. You can't be part of the study if you have other conditions like hepatitis B, certain cancers, or if you're pregnant. The study lasts 48 weeks with regular checks to see how well the medicine works.
- The study lasts 48 weeks.
- Participants must have HIV-1 and be new to HIV treatment.
- Regular visits are needed to monitor health and treatment effects.